Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof
US-2018261774-A1 · Sep 13, 2018 · US
Ether linked triazoles as NRF2 activators
US11059816B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11059816-B2 |
| Application number | US-201716468777-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 11, 2017 |
| Priority date | Dec 15, 2016 |
| Publication date | Jul 13, 2021 |
| Grant date | Jul 13, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:
First claim
Opening claim text (preview).
What is claimed is: 1. A compound which is (R)-3-(3-(((R)-2-Ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)-2,2-dimethyl-3-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)propanoic acid, or a pharmaceutically acceptable salt thereof. 2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient. 3. A compound which is (R)-3-((1-Ethyl-1H-1,2,3-triazol-4-yl)methoxy)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)-2,2-dimethylpropanoic acid, or a pharmaceutically acceptable salt thereof. 4. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles · CPC title
Drugs for disorders of the respiratory system · CPC title
Ortho-condensed systems · CPC title
- C07D419/12Primary
linked by a chain containing hetero atoms as chain links · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11059816B2 cover?
- The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:
- Who is the assignee on this patent?
- Glaxosmithkline Ip Dev Ltd, Astex Therapeutics Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D419/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 13 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).